The Society of Gynecologic Oncology (SGO) and the Association of Community Cancer Centers (ACCC) have been awarded a joint independent medical education grant from AstraZeneca and Merck. Together, SGO and ACCC will offer four accredited webinars (live and enduring) and up to six additional non-accredited media presentations on the topic of delivering personalized medicine in a community setting.
Listeners will learn about the importance of genetic testing for ovarian cancer from a genetic counselor and a physician, and most importantly, from a patient.
Moderator: Ashley Stuckey, MD
Speakers: Todd Tillmanns, MD, FACOG, West Cancer Center, and Leigha Senter-Jamieson, MS, CGC, The Ohio State University Wexner Medical Center.
Every patient with ovarian cancer should be offered testing aimed at informing targeted therapeutic decisions. This quick-reference, non-exhaustive guide provides a snapshot of germline and somatic testing options available for patients with ovarian cancer. Physicians and patients alike are encouraged to reference this PDF to printable postcard for more information about various labs, counseling options, and insurance information.
A round table discussion with a range of experts from academic centers to small community practice present examples of integrating palliative care in a variety of practice settings.
Moderator: Melissa Hardesty, MD, Alaska Women’s Cancer Care
In the fast-paced world of PARP inhibitor approvals in both the setting of maintenance and therapy in ovarian cancer, this panel of experts will assist practitioners to understand how to order germline and somatic testing for BRCA and HRD mutations. Speakers will discuss sequencing of PARP inhibitors as well as mitigating side effects. Additionally, they will discuss future directions for the use of PARP inhibitors as well as briefly discuss resistance to PARP inhibitors.
Moderator: John Farley, MD, COL, FACOG, FACS, Dignity Health – Cancer Institute, St. Joseph’s Hospital and Medical Center
William Burke, MD, Stony Brook University Cancer Center
Melissa Hardesty, MD, MPH, Alaska Women’s Cancer Care
Premal Thaker, MD, MS, Washington University in St. Louis, Siteman Cancer Center
Ashley Stuckey, MD, Brown University, Women and Infants Hospital
Todd Tillmanns, MD, FACOG, West Cancer Center
Jeff Lin, MD, City of Hope Medical Group
Roisin O’Cearbhaill, MD, Memorial Sloan Kettering Cancer Center
Charles Drescher, MD, Swedish Cancer Institute
John Farley, MD, COL, FACOG, FACS, Dignity Health Cancer Institute, St. Joseph’s Hospital and Medical Center
Leigha Senter-Jamieson, MS, CGC, The Ohio State University Wexner Medical Center
Medical oncologists, gynecologic oncologists, obstetrician-gynecologists, primary care physicians, advanced practice providers (nurse practitioners, physician assistants, oncology pharmacists), oncology nurses, pathologists, and other healthcare professionals (HCPs) involved in treating patients with ovarian cancer.
At the end of this educational initiative, participants should be able to:
The live/online webinars will each offer the following credits:
Non-accredited educational materials: podcasts, case reviews, and other educational resources/tools.
The impact of participating in this initiative on clinical performance related to the optimal management of ovarian cancer will be assessed by comparing the response for pre-activity and post-activity tests (also designed by the Steering Committee). The outcomes analysis will assess the effectiveness of the programs in changing knowledge and competence, and intent to change behavior among learners in the following areas:
For more information about the project, please contact Sandra Megally, Senior Program Manager, ACCC Provider Education.
This activity is supported by independent medical education grants from AstraZeneca and Merck.